Gilberto Prudencio serves as the Director of Business Development for the Americas at Rigaku Corporation, where he plays a pivotal role in driving the company's expansion in the life sciences sector following the strategic acquisition of MILabs. With over 20 years of experience in the...
Gilberto Prudencio serves as the Director of Business Development for the Americas at Rigaku Corporation, where he plays a pivotal role in driving the company's expansion in the life sciences sector following the strategic acquisition of MILabs. With over 20 years of experience in the healthcare, life sciences, pharmaceutical, and academic markets, Gilberto has successfully designed and executed innovative go-to-market strategies that leverage both direct and partner-driven sales programs. His expertise spans a diverse range of technologies, including software solutions, medical devices, molecular imaging, and bioinformatics, making him a key asset in navigating the complexities of these industries.
At Rigaku, Gilberto is instrumental in integrating MILabs’ advanced preclinical imaging modalities—such as PET, SPECT, Optical Imaging, and CT—with Rigaku's established X-ray analysis capabilities. This integration not only enhances Rigaku's product offerings but also positions the company as a leader in multi-modality imaging solutions. His acute ability to quickly assimilate and articulate complex technological portfolios has been crucial in fostering partnerships and driving sales operations across the Americas.
In addition to his strategic oversight, Gilberto actively participates in industry conferences, where he shares insights on imaging technologies and their applications in drug discovery and nuclear medicine. His commitment to advancing the field is reflected in his hands-on approach to product marketing and image processing, ensuring that Rigaku remains at the forefront of innovation in the life sciences arena. Through his leadership, Rigaku is poised to make significant strides in enhancing research capabilities and improving patient outcomes across the healthcare landscape.
